Anti-Leprosy Vaccine (Hansen’s Disease Vaccine)

Packyanathan, Jerusha Santa; Packyanathan, Ira Christabel; Balini, Annalisa

doi:10.1007/978-981-15-2195-9_24

Cited by 2 publications

(1 citation statement)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The BCG vaccine, initially used for the prevention of M. tuberculosis, has been implemented against leprosy, with protective effects in the range of 26-41% [28]. However, the efficacy declined over time and showed better results in women [45]. Antigens from the Indian Cancer Research Center (ICRC) bacillus revealed cross-reactivity with M. leprae and can be administered as a single dose at a sustainable antibody level [46].…”

Section: Leprosy Preventionmentioning

confidence: 99%

Diagnosis and Treatment of Leprosy in Taiwan during the COVID-19 Pandemic: A Retrospective Study in a Tertiaty Center

Hsieh,

Hsiao

2023

Diagnostics

View full text Add to dashboard Cite

Currently, over 200,000 new cases of leprosy are reported annually worldwide. Although leprosy was thought to have been eradicated in Taiwan, a few new cases still occur annually. Protean clinical manifestations of leprosy and immunological reactions result in delayed diagnoses. In addition, drug-resistant leprosy is emerging and poses treatment challenges. In this retrospective study, we collected and analyzed the clinicopathological features, leprosy type, treatment response, and relapse rate of patients with leprosy in our hospital between January 2009 and November 2022. We found that 54% of patients were Indonesian, and borderline lepromatous leprosy was predominant (39%); moreover, histoid leprosy and the Lucio phenomenon were also reported. Polymerase chain reaction analysis identified four positive cases, including a dapsone-resistant (4%) case. Our findings indicated good control of leprosy and a lower rate of dapsone resistance than that reported by the World Health Organization (4% vs. 13%) from 2009 to 2015. We found that the patient profile in terms of the treatment duration, recurrence rate, systemic symptoms, and neurological symptoms did not differ between before and during the pandemic. We report the recent advances in leprosy diagnosis, drug-resistant gene mutations, post-exposure prophylaxis, vaccination, and the effect of coronavirus disease 2019 on leprosy to facilitate updated leprosy diagnosis and management.

show abstract

Section: Leprosy Preventionmentioning

confidence: 99%